Resmetirom is an oral agonist of the receptor β for the thyroid hormone that has been approved in the United States of America in 2024 due to the encouraging results from the MAESTRO-NASH trial, a phase III trial in non-cirrhotic MASH patients with stage 2–3 fibrosis. Here, TG is linked to metabolic dysfunction-associated steatohepatitis.